Brighter and FRISQ initiate partnership to strengthen the infrastructure for digital healthcare.
Brighter and FRISQ have initiated a strategic partnership to strengthen the infrastructure and increase the information flow in the healthcare sector, as well as simplify the implementation of distance monitoring in diabetes care. The ambition is to provide a basis for better treatment of patients during the time between their hospital visits, through new digital services and mobile products.
– FRISQ is an ambitious and innovative company at the forefront of developing healthcare solutions for the future, says Truls Sjöstedt, Brighter's CEO and founder. A more data-driven care and an increased flow of information between, for example, caregivers and patients will be required in the future in order for the healthcare sector to be able to continue to deliver good care at a reasonable cost. The companies complement each other very well and we see a variety of positive synergies arising through this partnership.
FRISQ, listed on NASDAQ First North, has a unique mix of competences from the healthcare sector, pharmacy industry and IT development. The company develops digital services that are a daily support for healthcare professionals, providing patients new opportunities to become more involved in their own care.
– For us, it is a key strategy to work with innovative companies that have devices in different areas, says Martin Irding, CEO Frisq. Brighter is one of the most prominent companies in facilitating diabetic patients in their everyday life through the Actiste service, making Brighter a highly interesting company to collaborate with. The goal is to enable patients to share data, such as blood sugar values, from Actiste to the healthcare provider as part of a healthcare plan in FRISQ Care.
For more information, please contact:
Truls Sjöstedt, CEO
Telefon: +46 709 73 46 00
E-post: truls.sjostedt@brighter.se
Henrik Norström, COO
Telefon: +46 733 40 30 45
E-post: henrik.norstrom@brighter.se
About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of the most serious healthcare problems: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and close associates, healthcare providers, research, pharmaceutical industry and society. www.brighter.se
About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injection, and automatic logging and timing of all activity are done in a single unit. Actiste is connected via an autonomous and secure mobile connection, the information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed.
Validated user-generated data, such as as test results, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives ' concerns, and release enormous healthcare resources. www.actiste.com
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic Holding AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 CEST on March 26, 2018.